| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
9,450,000 |
| Market
Cap: |
51.12(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$3.15 - $6.74 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Diagnostic Substances |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Achieve Life Sciences is a pharmaceutical company engaged in the development and commercialization of cytisinicline for smoking cessation and nicotine addiction. Co.'s product candidate, cytisinicline, is a naturally occurring plant-based alkaloid from the seeds of the Laburnum anagyroides plant. Cytisinicline is structurally similar to nicotine and has a dual-acting mechanism of action that is both agonistic and antagonistic. Cytisinicline interacts with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms through agonistic binding to nicotine receptors and by reducing the reward and satisfaction associated with nicotine through antagonistic properties.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
20,000 |
20,000 |
25,000 |
47,000 |
| Total Buy Value |
$91,700 |
$91,700 |
$119,200 |
$119,200 |
| Total People Bought |
2 |
2 |
2 |
2 |
| Total Buy Transactions |
2 |
2 |
3 |
4 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-25 |
2023-11-24 |
2023-05-26 |
2022-05-26 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bencich John |
CFO & COO |
• – – |
2018-08-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,443 |
1,578 |
|
- |
|
| Jacobs Cindy |
EVP, CMO |
• – – |
2018-08-13 |
4 |
D |
$2.78 |
$1,312 |
D/D |
(472) |
1,810 |
|
- |
|
| Jacobs Cindy |
EVP, CMO |
• – – |
2018-08-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,486 |
2,282 |
|
- |
|
| Bencich John |
CFO |
• – – |
2017-09-08 |
4 |
D |
$3.09 |
$460 |
D/D |
(149) |
1,358 |
|
- |
|
| Bencich John |
CFO |
• – – |
2017-09-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
454 |
1,507 |
|
- |
|
| Cormack Scott Daniel |
Director |
– • – |
2017-09-08 |
4 |
D |
$3.09 |
$4,607 |
D/D |
(1,491) |
14,810 |
|
- |
|
| Schacter Robert |
10% Owner |
– – • |
2017-08-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,827,426 |
|
- |
|
| Stewart Richard Alistair |
Chairman & CEO |
• • – |
2017-08-01 |
4/A |
A |
$0.00 |
$0 |
I/I |
248,279 |
176,418 |
|
- |
|
| Stewart Richard Alistair |
Chairman & CEO |
• • – |
2017-08-01 |
4/A |
A |
$0.00 |
$0 |
D/D |
1,950,309 |
1,950,309 |
|
- |
|
| Clarke Anthony |
President & CSO |
• • – |
2017-08-01 |
4/A |
A |
$0.00 |
$0 |
I/I |
1,074,681 |
176,418 |
|
- |
|
| Clarke Anthony |
President & CSO |
• • – |
2017-08-01 |
4/A |
A |
$0.00 |
$0 |
D/D |
550,455 |
550,455 |
|
- |
|
| Cormack Scott Daniel |
Director |
– • – |
2017-08-01 |
4 |
OE |
$0.00 |
$0 |
I/I |
1,590 |
9,685 |
|
- |
|
| Cormack Scott Daniel |
Director |
– • – |
2017-08-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,125 |
16,302 |
|
- |
|
| Clarke Anthony |
Chief Scientific Officer |
• • – |
2017-08-01 |
4 |
A |
$0.00 |
$0 |
I/I |
10,607,225 |
6,364,335 |
|
- |
|
| Clarke Anthony |
Chief Scientific Officer |
• • – |
2017-08-01 |
4 |
A |
$0.00 |
$0 |
D/D |
6,364,335 |
6,364,335 |
|
- |
|
| Stewart Richard Alistair |
President & CEO |
• • – |
2017-08-01 |
4 |
A |
$0.00 |
$0 |
I/I |
848,578 |
848,578 |
|
- |
|
| Stewart Richard Alistair |
President & CEO |
• • – |
2017-08-01 |
4 |
A |
$0.00 |
$0 |
D/D |
22,487,319 |
22,487,319 |
|
- |
|
| Jacobs Cindy |
EVP, CMO |
• – – |
2017-06-12 |
4 |
D |
$0.36 |
$588 |
D/D |
(1,633) |
87,726 |
|
- |
|
| Jacobs Cindy |
EVP, CMO |
• – – |
2017-06-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,000 |
89,359 |
|
- |
|
| Cormack Scott Daniel |
President and CEO |
• • – |
2017-06-12 |
4 |
OE |
$0.00 |
$0 |
I/I |
5,000 |
89,055 |
|
- |
|
| Cormack Scott Daniel |
President and CEO |
• • – |
2017-06-12 |
4 |
D |
$0.36 |
$1,610 |
D/D |
(4,472) |
144,953 |
|
- |
|
| Cormack Scott Daniel |
President and CEO |
• • – |
2017-06-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,375 |
149,425 |
|
- |
|
| Cormack Scott Daniel |
President and CEO |
• • – |
2017-01-10 |
4 |
OE |
$0.00 |
$0 |
I/I |
10,312 |
84,055 |
|
- |
|
| Cormack Scott Daniel |
President and CEO |
• • – |
2017-01-10 |
4 |
D |
$0.63 |
$6,105 |
D/D |
(9,690) |
140,050 |
|
- |
|
| Cormack Scott Daniel |
President and CEO |
• • – |
2017-01-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
20,312 |
149,740 |
|
- |
|
283 Records found
|
|
Page 4 of 12 |
|
|
